acute ischemic stroke: Groups of 8 patients (6 active, 2 placeboes) were planned to receive twice-daily treatment, with l00 mg, 200 mg, 300 mg, 400 mg, 500 mg, or 600 mg remacemide hydrochloride given as 2 intravenous infusions followed by 6 days' oral treatment. The maximum well-tolerated dose for remacemide hydrochloride in acute stroke is 400 mg BID. Epilepsy: Two parallel group trials were included representing 514 individuals. Daily doses of 300, 600, 800 and 1200 mg of remacemide were tested. Regression models did, however, suggest a significant effect for 800-1200mg remacemide per day

remacemide and its anticonvulsant metabolite 1,2-diphenyl-2-propylamine monohydrochloride (desglycinyl remacemide; DGR) a low-affinity NMDA receptor antagonist, were investigated using primary rat cortical neuronal cultures. Exposure of cortical cultures to NMDA (100 microM) for 15 min killed 85% of the neurons during the next 24 h. This neurotoxicity was blocked in a concentration-dependent manner by adding DGR (5-20 microM), but not its remacemide precursor (10-100 microM), to the cultures during the time of NMDA exposure. This suggests that the neuroprotective, as well as the anticonvulsant, the activity of remacemide is mediated by DGR.